Introduction and Objective: Ramadan fasting is associated with dysglycemia risk in people living with diabetes (PLWD). This real-world study evaluated glycemic management in PLWD before, during, and after Ramadan fasting using continuous glucose monitoring (CGM). Methods: Retrospective analysis of Dexcom CGM users (≥18 years) living in an Arab Gulf country, Jordan, or Lebanon, and self-reported living with diabetes and fasted during Ramadan at least once between 2020-2025 (confirmed via survey). Outcomes were change in CGM metrics between the month before, during, and after Ramadan. Subgroup analyses (e.g., diabetes type, insulin therapy, age or ≥60 years, gender) were conducted. Results: A total of 103 participants completed the survey and met the inclusion criteria for analysis (70% CGM utilization during all periods) and were included in the analysis (see Table for demographics). Mean Level 1 hypoglycemic events per week significantly decreased during Ramadan compared to before and after (p0.05, Table). No other significant CGM metric differences were observed. Insulin therapy subgroup analysis showed multiple daily injection users observed significantly higher CV and rebound hyperglycemic events per week during all periods (data not shown). Conclusion: In this real-world, retrospective study of PLWD, glycemic management before, during, and after Ramadan fasting with use of CGM was maintained. Disclosure M.M. Hassanein: None. R.M. Alamoudi: None. J. Tomlin: Employee; Current; Dexcom, Inc. H. Yousri: None. C. Chen: Employee; Current; Dexcom, Inc., Google. Y. Xu: Employee; Current; Dexcom, Inc. L. Yang: Employee; Current; Dexcom, Inc. S. Jones: Employee; Current; Dexcom, Inc. C. Griffen: Employee; Current; Dexcom, Inc. M.E. Al-Sofiani: Speaker's Bureau; Ended; Medtronic, Dexcom, Inc. Research Support; Current; Dexcom, Inc. Research Support; Ended; Medtronic. Speaker's Bureau; Ended; Insulet Corporation, Abbott Diabetes, Sanofi.
HASSANEIN et al. (Fri,) studied this question.